Because the main purpose of our research group is elucidation of the pathophysiology of diabetes, we evaluated whether the improved WB is applicable for other peptide hormones and analogs involved in diabetes (Fig. 6a, insulin analogs; Fig. 6b, glucagon; Fig. 6c, GLP1s; Fig. 6d, somatostatins; Fig. 6e, ghrelins; and Fig. 6f, pancreatic polypeptide)12–16. Here, INS is linked to diabetes mellitus.